SHS.A. Holme

S.A. Holme

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


S.A. Holme has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • A.V. Anstey

    Department of Dermatology, Queen Margaret Hospital, Dunfermline KY12 0SU, U.K.Departments of Dermatology

    2 shared publications
  • G.H. Elder

    Medical Biochemistry and Immunology, University of Wales, School of Medicine, Heath Park, Cardiff CF14 4XN, U.K.

    2 shared publications
  • M.N. Badminton

    Medical Biochemistry and Immunology, University of Wales, School of Medicine, Heath Park, Cardiff CF14 4XN, U.K.

    2 shared publications
  • Andrew Yule Finlay

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK

    1 shared publication
  • P. Laidler

    Welsh Institute of Dermatology and Department of Histopathology, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, U.K.

    1 shared publication
  • P.J.A. Holt

    Welsh Institute of Dermatology and Department of Histopathology, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, U.K.

    1 shared publication

Latest Publications

  • Serum 25-hydroxyvitamin D in erythropoietic protoporphyria

    by S.A. Holme, A.V. Anstey, M.N. Badminton, G.H. Elder

    Vitamin D, produced by the action of sunlight on skin, is an important hormone for calcium homeostasis and has been implicated as tumour-protective agent. Some previous studies of photosensitive patients who actively avoid sunlight have failed to show convincing evidence of vitamin D insufficiency. The aim of this study was to characterize the vitamin D status of a large cohort of patients with erythropoietic protoporphyria (EPP). U.K. patients with EPP were recruited prospectively and seen locally by a single study investigator. A blood sample was taken for vitamin D assay. All blood analyses were performed in the same laboratory. A cohort of 201 patients with known EPP was seen over a 7-month period between January and July. Thirty-four patients (17%) were deficient in vitamin D and 126 (63%) had insufficient vitamin D. Both insufficiency and deficiency were significantly associated with the total erythrocyte protoporphyrin concentration and inversely with the time in minutes to the onset of symptoms following sunlight exposure. This is the first report of significant levels of vitamin D deficiency and insufficiency in a large cohort of patients with a photodermatosis. Such individuals are at risk of associated adverse events. In future, clinicians should consider monitoring 25-hydroxyvitamin D levels and instigating oral supplementation or dietary advice if appropriate.


  • Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life

    by S.A. Holme, A.V. Anstey, A.Y. Finlay, G.H. Elder, M.N. Badminton

    Erythropoietic protoporphyria (EPP) is a rare inherited photodermatosis that causes lifelong painful photosensitivity. Neither its full clinical spectrum nor its impact on quality of life (QoL) has been investigated in a large cohort of patients. To document the clinical features of EPP and its impact on QoL in a high proportion of all patients with EPP resident in the U.K. Patients with EPP were identified from U.K. clinical databases and assessed by the same clinical investigator over a 7-month period using a standardized proforma and validated adult (Dermatology Life Quality Index, DLQI) and children's (Children's Dermatology Life Quality Index, CDLQI) QoL questionnaires. Three hundred and eighty-nine living patients with EPP were identified, of whom 223 [114 females, 109 males; median age 34 years (range: 5-87), from 193 families] were investigated. Total erythrocyte porphyrin (TEP) was higher in males (median: 25.3 micromol L1) than females (median: 19.3 micromol L1). The median ages at onset and diagnosis were 1 and 12 years, respectively. Median times for onset of symptoms after sun exposure, onset of signs (oedema, erythema) and resolution of symptoms were 20 min, 6 h and 3 days, respectively. Most patients reported absence of protection by glass (92%), priming (85%), exacerbation by wind (68%), no family history of photosensitivity (56%), no symptoms during winter (56%) and had chronic skin lesions (79%). Symptoms changed little with age but improved during pregnancy in 47% of gravid women. Most patients used protective clothing and a sunscreen; 28% were taking beta-carotene and a further 56% had taken it; 29% were not under regular medical care. Two patients (1%) had liver failure and 8% reported gallstone disease. QoL was markedly impaired, with scores similar to those in severe dermatological disease (mean DLQI score 14.0, n = 176; mean CDLQI score 12.8, n = 44), indicating a large effect on patients' lives. DLQI scores correlated weakly with TEP (rs = 0.228; P = 0.002) and time to onset of symptoms (rs = -0.233; P = 0.002) but not with age at onset. EPP is a persistent, severely painful, socially disabling disease with a marked impact on QoL. Its diagnosis is often overlooked. None of TEP, age at onset nor time to onset of symptoms is a useful predictor of impaired QoL in individual patients.